Autoimmune Encephalitis

Migration, Crosslink

📖

Autoimmune Encephalitis

active

wiki page Created: 2026-04-02T07:20:13 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-diseases-autoimmune-encephalitis

📖 Wiki Page

diseases2853 wordssynced 2026-04-02

Overview

Pathway Diagram

flowchart TD A["Autoimmune Disease"] B["cGAS DNA Sensor"] C["NF-kappaB Transcription Factor"] D["Cytokines Inflammatory Mediators"] E["Astrocytes Glial Cells"] F["Inflammation Process"] G["Immune Response Pathway"] H["Innate Immunity Pathway"] I["Neurodegeneration Outcome"] J["Blood-Brain Barrier Disruption"] K["T Cell Activation"] L["Microglial Activation"] M["Therapeutic Targets"] N["Cancer Comorbidity"] B -->|"activates"| A A -->|"activates"| G A -->|"activates"| H A -->|"therapeutic_target"| C A -->|"associated_with"| F D -->|"regulates"| A E -->|"activates"| A F -->|"associated_with"| A G -->|"leads_to"| K H -->|"activates"| L C -->|"promotes"| F F -->|"causes"| J J -->|"leads_to"| I L -->|"secretes"| D K -->|"produces"| D A -->|"associated_with"| N C -->|"connects_to"| M D -->|"connects_to"| M style A fill:#006494,color:#e0e0e0 style B fill:#4a1a6b,color:#e0e0e0 style C fill:#4a1a6b,color:#e0e0e0 style D fill:#4a1a6b,color:#e0e0e0 style E fill:#4a1a6b,color:#e0e0e0 style F fill:#ef5350,color:#0d0d1a style G fill:#ef5350,color:#0d0d1a style H fill:#ef5350,color:#0d0d1a style I fill:#5d4400,color:#e0e0e0 style J fill:#ef5350,color:#0d0d1a style K fill:#ef5350,color:#0d0d1a style L fill:#ef5350,color:#0d0d1a style M fill:#1b5e20,color:#e0e0e0 style N fill:#6d3b00,color:#e0e0e0

...

Overview

Pathway Diagram

Mermaid diagram (expand to render)

Autoimmune encephalitis (AE) is a group of inflammatory brain disorders in which the immune system mistakenly attacks healthy brain tissue, leading to diverse neurological and psychiatric manifestations. Once considered rare, AE has emerged as one of the most common causes of encephalitis worldwide, with an incidence estimated at 10-13 per 100,000 person-years["@incidence2019"]. The condition encompasses a broad spectrum of clinical phenotypes, ranging from limbic encephalitis with prominent memory disturbances to diffuse encephalopathy with seizures, movement disorders, and autonomic dysfunction["@antibodymediated2017"].

The recognition of AE has revolutionized our understanding of previously enigmatic encephalitic syndromes. Since the discovery of anti-NMDA receptor (NMDAR) encephalitis in 2007[@nmdar2007], over 20 distinct autoantibody targets have been identified, each associated with characteristic clinical features, treatment responses, and prognoses. These antibodies target either neuronal surface antigens (NSAbs) or intracellular antigens, with significant implications for pathogenesis and therapeutic approaches["@autoimmune2020"].

Epidemiology and Risk Factors

Autoimmune encephalitis affects individuals across all age groups, though certain subtypes show characteristic age distributions. Anti-NMDAR encephalitis predominantly affects young adults, with a median age of 21 years and a strong female predominance (approximately 4:1 ratio), particularly in patients with ovarian teratomas[@antinmda2016]. In contrast, LGI1-associated limbic encephalitis more commonly affects older males, with a median age of 64 years[@lgi2015].

The overall incidence of AE has increased substantially over the past two decades, partly due to improved diagnostic awareness and testing capabilities. Population-based studies from Europe and North America indicate that AE now accounts for 20-30% of all encephalitis cases, surpassing infectious etiologies in many regions[@changing2020]. Approximately 70-80% of AE cases occur in individuals without known predisposing factors, while the remaining cases are associated with underlying neoplasms (paraneoplastic AE), infections (post-infectious AE), or other autoimmune disorders[@paraneoplastic2021].

Geographic and Seasonal Patterns

While AE occurs worldwide, some studies suggest regional variations in incidence and antibody prevalence. The peak incidence appears in winter and spring months for some subtypes, potentially reflecting seasonal infection patterns that trigger post-infectious autoimmunity[@incidence2019]. However, more research is needed to establish definitive seasonal patterns.

Genetic Associations

Certain human leukocyte antigen (HLA) alleles confer increased susceptibility to specific AE subtypes. HLA-DRB110:01 is strongly associated with anti-IgLON5 disease[@antiiglon2015], while HLA-DQB106:02 shows association with anti-NMDAR encephalitis in some populations. These genetic associations suggest underlying immune dysregulation as a predisposing factor[@hla2019].

Family history of autoimmune disease is reported in 15-20% of AE patients, with higher rates of autoimmune thyroid disease, type 1 diabetes, and systemic lupus erythematosus. This suggests a shared genetic susceptibility to immune dysregulation[@treatment2016].

Gender Distribution

Gender distribution varies by AE subtype:

Anti-NMDAR: Female predominance (4:1), especially with ovarian teratomas
LGI1 encephalitis: Male predominance (2:1)
CASPR2 encephalitis: Male predominance (3:1)
Anti-IgLON5: Equal distribution

These gender differences likely reflect hormonal influences on immune function and differential tumor associations.

Pathophysiology

Antibody-Mediated Mechanisms

The pathogenesis of autoimmune encephalitis involves distinct mechanisms depending on the antibody target. Antibodies against neuronal surface antigens typically cause reversible neuronal dysfunction through several mechanisms:

Internalization and modulation: Anti-NMDAR antibodies bind to the GluN1 subunit, causing receptor internalization and reduction of surface NMDAR density, leading to impaired synaptic transmission and cognitive deficits[@antinmda2008]

Functional blockade: Some antibodies, such as those targeting LGI1 or GABA_B receptor, interfere with ligand binding or channel function without causing receptor internalization[@lgi2012]

Complement activation: Antibodies against intracellular antigens (e.g., Hu, Ma2) are thought to mediate cytotoxicity through T-cell mechanisms rather than direct complement-mediated damage[@tcell2015]

Receptor Subunit Specificity

The NMDAR is composed of GluN1 and GluN2 (A-D) subunits. Anti-NMDAR antibodies primarily target the GluN1 subunit, which is essential for receptor function. The binding site localizes to the extracellular domain, and antibody binding can be displaced by exogenous agonists, suggesting competitive inhibition[@antinmda2008].

LGI1, a ligand for ADAM22, modulates AMPA receptor function. Anti-LGI1 antibodies disrupt this interaction, leading to impaired synaptic transmission and hyperexcitability. The characteristic faciobrachial dystonic seizures likely arise from disrupted temporal lobe circuitry[@faciobrachial2015].

Cellular Immune Response

Beyond humoral immunity, T-cell-mediated responses contribute significantly to tissue injury in AE. CD8+ cytotoxic T lymphocytes target neurons expressing cognate antigens, particularly in paraneoplastic encephalitis associated with intracellular antigen antibodies[@tcell2017]. Microglial activation and inflammatory cytokine production create a pro-inflammatory microenvironment that perpetuates neuronal injury[@microglial2020].

The blood-brain barrier (BBB) plays a critical role in AE pathogenesis. Disruption of the BBB allows peripheral antibodies and immune cells to enter the central nervous system, while also enabling CNS antigens to trigger peripheral immune responses. Studies using dynamic contrast-enhanced MRI have demonstrated BBB leakage in many AE patients, particularly in limbic structures[@diagnostic2016].

Neuroinflammatory Cascade

The inflammatory response in AE involves multiple cell types and signaling pathways:

Microglia: Activated microglia produce pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and reactive oxygen species[@microglial2020]
Astrocytes: Astrocyte dysfunction contributes to excitotoxicity and blood-brain barrier disruption
T-cells: CD8+ cytotoxic T cells mediate direct neuronal injury; regulatory T cells may be deficient
B-cells: Both autoantibody-producing plasma cells and antigen-presenting B cells contribute to pathogenesis[@relapse2016]

Paraneoplastic Mechanisms

Tumors expressing neuronal antigens trigger immune responses that cross-react with central nervous system tissues. The immune response involves both cellular and humoral mechanisms, with antibodies serving as markers of the underlying immune dysregulation rather than direct mediators of damage in many paraneoplastic syndromes[@paraneoplastic2015].

The most well-established paraneoplastic association is between ovarian teratomas and anti-NMDAR encephalitis. Teratoma cells contain neuronal tissue that expresses NMDAR, triggering an immune response that generates cross-reactive antibodies. Tumor resection often leads to clinical improvement, supporting this pathogenic mechanism[@antinmda2016].

Other paraneoplastic associations include:

Small cell lung cancer: Anti-Hu, Anti-CV2/CRMP5
Thymoma: Anti-LGI1, Anti-CASPR2, Anti-α3 nicotinic acetylcholine receptor
Testicular cancer: Anti-NMDAR (rare)

Clinical Features

Core Syndromes

Anti-NMDAR Encephalitis

Anti-NMDAR encephalitis represents the most common and well-characterized AE subtype. The classic presentation involves a prodromal phase with headache, fever, and viral-like symptoms, followed by psychiatric features including anxiety, agitation, behavioral changes, and psychosis[@psychiatric2014]. The psychiatric manifestations can be severe enough to lead to initial psychiatric admission before neurological diagnosis.

Seizures occur in over 80% of patients, often progressing to refractory status epilepticus. Movement disorders are common, particularly orofacial dyskinesias, choreoathetosis, and dystonia. Autonomic dysfunction manifests as tachycardia, hypertension, hyperthermia, and can progress to severe dysautonomia requiring intensive care support[@autonomic2016].

The disease course typically progresses through characteristic stages:

Prodromal phase: Headache, fever, fatigue (days 1-2)

Psychiatric phase: Behavioral changes, psychosis (days 2-14)

Seizure phase: Refractory seizures, status epilepticus (weeks 2-4)

Recovery phase: Gradual improvement over months to years

Limbic Encephalitis

Limbic encephalitis presents with the triad of seizures, memory dysfunction, and psychiatric symptoms. LGI1 encephalitis typically presents with faciobrachial dystonic seizures (FBDS), characterized by brief, unilateral facial and arm contractions, often preceding the development of limbic encephalitis by days to weeks[@faciobrachial2015]. These seizures are highly characteristic and should prompt immediate antibody testing.

Cognitive impairment often includes prominent anterograde amnesia with relative preservation of other cognitive domains. Patients may develop emotional lability and personality changes, reflecting limbic system involvement.

Anti-IgLON5 Disease

Anti-IgLON5 disease presents as a unique syndrome of progressive insomnia, dysarthria, dysphagia, gait disturbance, and cognitive decline. Polysomnography reveals abnormal sleep architecture with REM sleep behavior disorder. The disease has strong associations with HLA-DRB1*10:01 and may have a neurodegenerative component[@antiiglon2015].

Associated Symptoms and Signs

Beyond the core syndromes, AE can present with:

Movement disorders: Tremor, myoclonus, rigidity, ataxia, catatonia
Cerebellar symptoms: Nystagmus, dysmetria, gait instability
Brainstem involvement: Cranial nerve palsies, respiratory dysfunction, dysphagia
Peripheral nerve involvement: Peripheral neuropathy, autonomic ganglionopathy
Systemic features: Weight loss, thermal dysregulation, skin changes

Seizure Semiology

Seizures in AE are often refractory and may present with various semiologies:

Focal seizures with impaired awareness
Generalized tonic-clonic seizures
Faciobrachial dystonic seizures (LGI1)
Epilepsia partialis continua
Status epilepticus (common in anti-NMDAR)

EEG findings correlate poorly with seizure burden, and subclinical seizures may persist despite suppressive therapy.

Diagnosis

Diagnostic Criteria

The 2016 diagnostic criteria for AE proposed by Graus et al. provide a structured approach to diagnosis[@diagnostic2016]. The criteria require:

Subacute onset (rapid progression <3 months) of working memory deficits, altered mental status, or psychiatric symptoms

One or more of:

New focal CNS findings
Seizures not explained by known disorders
CSF pleocytosis (>5 cells/μL)
MRI features suggestive of encephalitis

3. Exclusion of alternative causes

Positive AE-specific antibody in serum or CSF

A definite diagnosis requires the combination of clinical features with confirmatory antibody testing. A probable diagnosis can be made when clinical features are characteristic but antibody testing is negative or unavailable.

Differential Diagnosis

AE must be differentiated from:

Infectious encephalitis: HSV, VZV, enteroviruses, arboviruses
Metabolic encephalitis: Wernicke's, hepatic encephalopathy
Neurodegenerative diseases: FTD, AD, CJD
Psychiatric conditions: Primary psychosis, catatonia
Other inflammatory conditions: CNS vasculitis, neurosarcoidosis
Toxic exposures: Drug-induced encephalopathy

Key distinguishing features include subacute onset, CSF inflammation, and characteristic MRI findings.

Laboratory Findings

Cerebrospinal Fluid Analysis

CSF findings in AE are variable but commonly include:

Lymphocytic pleocytosis (10-100 cells/μL) in 60-80% of cases
Elevated protein in 30-50% of cases
Oligoclonal bands in approximately 40% of cases
Normal glucose consistently
Elevated neurofilament light chain (NfL) in severe cases[@fdgpet2017]

Neuroimaging

MRI findings depend on the AE subtype:

Limbic encephalitis: T2/FLAIR hyperintensity in medial temporal lobes, typically unilateral initially
Anti-NMDAR encephalitis: Often normal early, may develop cortical/subcortical changes in basal ganglia, cerebellum
Anti-IgLON5: May show brainstem or cerebellar atrophy
Diffuse involvement: May show multifocal white matter changes in severe cases

FDG-PET can reveal hypometabolism in temporal lobes or diffuse cortical hypermetabolism in anti-NMDAR encephalitis[@fdgpet2017]. PET imaging may be more sensitive than MRI for detecting early changes.

Electroencephalography

EEG is abnormal in 90% of AE patients, showing:

Generalized or focal slowing in 70%
Epileptiform discharges in 40%
Extreme delta brush pattern in anti-NMDAR encephalitis (specific but not sensitive)
Periodic lateralized epileptiform discharges (PLEDs) in some cases

Antibody Testing

Serum and CSF testing should be performed simultaneously, as some antibodies (particularly anti-NMDAR) have higher sensitivity in CSF[@csf2018]. Cell-based assays (CBA) are the gold standard for surface antibody detection, with immunohistochemistry and Western blot serving as supplementary techniques.

Antibody categories:

Surface antigens (NSAbs): NMDAR, LGI1, CASPR2, GABA_BR, AMPAR

Intracellular antigens: Hu, Ma2, CV2/CRMP5, amphiphysin

Synaptic antigens: Synapsin, GRIN2B

The antibody target influences prognosis and treatment response, making accurate identification crucial.

Treatment

First-Line Immunotherapy

First-line therapies should be initiated as soon as AE is suspected:

Corticosteroids: Methylprednisolone 1g/day for 3-5 days, followed by oral prednisone taper over 2-6 months

Intravenous immunoglobulin (IVIG): 0.4g/kg/day for 5 days

Plasma exchange: 5-7 exchanges over 10-14 days

These treatments can be used alone or in combination, with early intervention associated with improved outcomes[@treatment2016]. Combination therapy (corticosteroids + IVIG or plasma exchange) is often recommended for severe cases.

Second-Line Immunotherapy

For patients with inadequate response to first-line therapy (persistent symptoms >2-4 weeks):

Rituximab: Anti-CD20 monoclonal antibody depleting B-cells at 375mg/m² weekly for 4 weeks
Cyclophosphamide: Alkylating agent for severe, refractory cases (750mg/m² monthly)
Mycophenolate mofetil: 1-1.5g twice daily for maintenance therapy
Azathioprine: 2-3mg/kg/day for maintenance

Second-line therapy is required in approximately 30-50% of anti-NMDAR encephalitis cases[@relapse2016].

Tumor Removal

In paraneoplastic AE, tumor identification and removal is crucial:

Ovarian teratoma in anti-NMDAR encephalitis (found in 20-50% of female patients)
Small cell lung cancer in anti-Hu, anti-CV2/CRMP5 encephalitis
Thymoma in anti-LGI1, anti-CASPR2 encephalitis
Testicular tumors in some male patients

Comprehensive cancer screening should be performed in all AE patients, including:

CT chest/abdomen/pelvis
Pelvic ultrasound (females)
Testicular ultrasound (males)
Mammogram and Pap smear as age-appropriate

Supportive Care

Aggressive supportive management is often required:

Seizure control with antiepileptic drugs (often requires multiple agents)
Management of dysautonomia (autonomic storms, arrhythmias)
Intensive care for status epilepticus and respiratory failure
Physical, occupational, and speech therapy
Psychiatric management during recovery
Nutritional support for dysphagia

Prognosis

Outcomes vary substantially based on AE subtype and treatment timing:

Anti-NMDAR encephalitis: Approximately 80% achieve good recovery (mRS 0-2) with aggressive immunotherapy, though recovery may take months to years. Relapse occurs in approximately 10-20% of patients[@relapse2016]. Persistent cognitive deficits occur in up to 25% of patients.
Limbic encephalitis (LGI1, GABA_BR): Generally favorable prognosis with early immunotherapy, though cognitive deficits often persist. Approximately 70% achieve functional independence.
Anti-IgLON5 disease: More progressive course, with approximately 30% mortality at 5 years despite immunotherapy. Most patients require ongoing immunosuppressive therapy[@antiiglon2015].
Paraneoplastic encephalitis with intracellular antigens: Generally poorer outcomes, with permanent neurological deficits common even with aggressive treatment.

Predictors of Outcome

Positive prognostic factors include:

Early immunotherapy (within 4 weeks of symptom onset)
Absence of ICU admission during acute phase
Female sex in anti-NMDAR encephalitis
Tumor resection in paraneoplastic cases
Lower baseline antibody titers

Negative prognostic factors include:

Delayed treatment (>8 weeks)
Refractory status epilepticus
Intensive care admission
High initial antibody titers
Anti-Hu or anti-Ma2 antibodies

Relationship to Neurodegenerative Diseases

Emerging evidence links autoimmune encephalitis to neurodegenerative processes. Some patients with AE develop persistent cognitive deficits resembling frontotemporal dementia or Alzheimer's disease[@cognitive2019]. The long-term cognitive outcomes of AE survivors are an area of active investigation.

Conversely, patients with neurodegenerative diseases may develop AE-like autoimmunity, complicating diagnostic differentiation[@autoimmunity2022]. The presence of autoantibodies in neurodegenerative diseases may represent:

True paraneoplastic phenomena secondary to tumor antigens

Epiphenomenon of blood-brain barrier breakdown

Primary immune dysregulation contributing to neurodegeneration

Recent studies have identified autoantibodies in patients with Alzheimer's disease, Parkinson's disease, and frontotemporal dementia, raising questions about whether autoimmunity contributes to or is a consequence of neurodegeneration.

AE as a Neurodegenerative Model

Anti-IgLON5 disease represents an intriguing intersection between autoimmunity and neurodegeneration. The presence of tau pathology in some patients, combined with HLA-DRB1*10:01 association and progressive course, suggests underlying neurodegeneration triggered or exacerbated by autoimmune mechanisms[@antiiglon2015].

Pediatric Considerations

Autoimmune encephalitis in children has distinct features:

Anti-NMDAR encephalitis is the most common cause of AE in children
Higher rates of infectious triggers (HSV, EBV)
Often better outcomes than adults with aggressive treatment
Distinct presentation with seizures and movement disorders more prominent
Ovarian teratomas less common in pre-adolescent children

Pediatric AE requires specialized management including developmental support and school reintegration planning.

Animal Models and Experimental Insights

Animal models have provided crucial insights into AE pathogenesis:

Anti-NMDAR encephalitis: Passive transfer of patient antibodies to mice causes behavioral deficits and NMDAR internalization[@antinmda2008]
LGI1 encephalitis: Animal models demonstrate disrupted LGI1-ADAM22 signaling and impaired synaptic plasticity
Targeted therapies: Experimental approaches include antigen-specific tolerance induction and antibody adsorption

These models enable testing of novel therapeutic strategies before clinical translation.

Economic and Healthcare Burden

AE imposes significant healthcare burden:

Average hospital stay: 30-60 days
ICU admission required in 30-50% of cases
Long-term rehabilitation costs
Lost productivity due to cognitive sequelae

Early diagnosis and treatment reduce overall costs by shortening hospital stay and improving outcomes.

Quality of Life Considerations

AE survivors face significant quality of life challenges:

Cognitive impairment affecting daily functioning
Persistent fatigue and exercise intolerance
Psychiatric sequelae including anxiety and depression
Social and occupational reintegration difficulties

Comprehensive follow-up programs addressing physical, cognitive, and psychological domains are essential.

Future Directions

Current research focuses on:

Understanding antibody pathogenicity and developing targeted therapies
Identifying novel autoantibody targets using proteomic approaches
Biomarker development for treatment response and prognosis (CSF NfL, anti-NMDAR titers)
Long-term outcomes and quality of life studies
Mechanisms of relapse and tolerance induction
Role of gut microbiome in AE pathogenesis and treatment response
Development of antigen-specific immunotherapy approaches

References

[Unknown, Incidence of autoimmune encephalitis: a population-based study (2019)](https://pubmed.ncbi.nlm.nih.gov/33145817/)

[Unknown, Antibody-mediated encephalitis: a treatable cause of dementia (2017)](https://pubmed.ncbi.nlm.nih.gov/25935244/)

[Unknown, NMDAR encephalitis: clinical features, diagnosis and therapy (2007)](https://doi.org/10.1056/NEJMoa072749)

[Unknown, Autoimmune encephalitis: expanding the spectrum of neurological manifestations (2020)](https://pubmed.ncbi.nlm.nih.gov/31953167/)

[Unknown, Anti-NMDA receptor encephalitis: clinical features and long-term outcomes (2016)](https://pubmed.ncbi.nlm.nih.gov/28671691/)

[Unknown, LGI1 encephalitis: clinical features and treatment outcomes (2015)](https://pubmed.ncbi.nlm.nih.gov/26512650/)

[Unknown, Changing patterns in autoimmune encephalitis: a population-based study (2020)](https://pubmed.ncbi.nlm.nih.gov/33210265/)

[Unknown, Paraneoplastic autoimmune encephalitis: clinical features and tumor associations (2021)](https://pubmed.ncbi.nlm.nih.gov/34152947/)

[Unknown, Anti-NMDA receptor antibodies cause receptor internalization (2008)](https://doi.org/10.1016/j.neuron.2008.10.016)

[Unknown, LGI1 antibodies cause limbic dysfunction without receptor internalization (2012)](https://pubmed.ncbi.nlm.nih.gov/22197931/)

[Unknown, T-cell mediated pathogenesis in paraneoplastic encephalitis (2015)](https://pubmed.ncbi.nlm.nih.gov/25425667/)

[Unknown, CD8+ T-cell cytotoxicity in autoimmune encephalitis (2017)](https://pubmed.ncbi.nlm.nih.gov/28887056/)

[Unknown, Microglial activation in autoimmune encephalitis (2020)](https://pubmed.ncbi.nlm.nih.gov/32795489/)

[Unknown, Paraneoplastic autoimmunity: mechanisms and clinical implications (2015)](https://pubmed.ncbi.nlm.nih.gov/26537561/)

[Unknown, Psychiatric manifestations of anti-NMDA receptor encephalitis (2014)](https://pubmed.ncbi.nlm.nih.gov/20587456/)

[Unknown, Autonomic dysfunction in anti-NMDA receptor encephalitis (2016)](https://pubmed.ncbi.nlm.nih.gov/28671691/)

[Unknown, Faciobrachial dystonic seizures precede LGI1 encephalitis (2015)](https://pubmed.ncbi.nlm.nih.gov/25238599/)

[Unknown, Anti-IgLON5 disease: a novel tauopathy (2015)](https://pubmed.ncbi.nlm.nih.gov/26028666/)

[Unknown, Diagnostic criteria for autoimmune encephalitis: Graus criteria (2016)](https://pubmed.ncbi.nlm.nih.gov/27057869/)

[Unknown, FDG-PET and CSF biomarkers in autoimmune encephalitis (2017)](https://pubmed.ncbi.nlm.nih.gov/28359061/)

[Unknown, CSF vs serum antibody testing in autoimmune encephalitis (2018)](https://pubmed.ncbi.nlm.nih.gov/30555078/)

[Unknown, Treatment outcomes in autoimmune encephalitis (2016)](https://pubmed.ncbi.nlm.nih.gov/28671691/)

[Unknown, Relapse in anti-NMDA receptor encephalitis (2016)](https://pubmed.ncbi.nlm.nih.gov/28671691/)

[Unknown, Cognitive outcomes in autoimmune encephalitis (2019)](https://pubmed.ncbi.nlm.nih.gov/33145817/)

[Unknown, Autoimmunity in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35668690/)

[Unknown, HLA associations in autoimmune encephalitis (2019)](https://pubmed.ncbi.nlm.nih.gov/29855555/)

📖 View canonical wiki page →

Related Entities

diseases-autoimmune-encephalitis

▸Metadataorigin_type: v1_polymorphic_backfill

slug	diseases-autoimmune-encephalitis
kg_node_id	None
entity_type	diseases
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-bb1b772d7e90
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'diseases-autoimmune-encephalitis'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

35%

Debates

0

Incoming

7

Outgoing

7

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Autoimmune Encephalitis

Overview

Pathway Diagram

Overview

Pathway Diagram

Epidemiology and Risk Factors

Geographic and Seasonal Patterns

Genetic Associations

Gender Distribution

Pathophysiology

Antibody-Mediated Mechanisms

Receptor Subunit Specificity

Cellular Immune Response

Neuroinflammatory Cascade

Paraneoplastic Mechanisms

Clinical Features

Core Syndromes

Anti-NMDAR Encephalitis

Limbic Encephalitis

Anti-IgLON5 Disease

Associated Symptoms and Signs

Seizure Semiology

Diagnosis

Diagnostic Criteria

Differential Diagnosis

Laboratory Findings

Cerebrospinal Fluid Analysis

Neuroimaging

Electroencephalography

Antibody Testing

Treatment

First-Line Immunotherapy

Second-Line Immunotherapy

Tumor Removal

Supportive Care

Prognosis

Predictors of Outcome

Relationship to Neurodegenerative Diseases

AE as a Neurodegenerative Model

Pediatric Considerations

Animal Models and Experimental Insights

Economic and Healthcare Burden

Quality of Life Considerations

Future Directions

See Also

References

💬 Discussion